VIVORYON THERAPEUTICS NV (VVY.AS) Stock Price & Overview
AMS:VVY • NL00150002Q7
The current stock price of VVY.AS is 1.378 EUR. Today VVY.AS is down by -0.43%. In the past month the price decreased by -3.64%. In the past year, price decreased by -27.01%.
VVY.AS Key Statistics
- Market Cap
- 40.803M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.48
- Dividend Yield
- N/A
VVY.AS Stock Performance
VVY.AS Stock Chart
VVY.AS Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to VVY.AS. When comparing the yearly performance of all stocks, VVY.AS is a bad performer in the overall market: 89.08% of all stocks are doing better.
VVY.AS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VVY.AS. VVY.AS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
VVY.AS Earnings
VVY.AS Forecast & Estimates
7 analysts have analysed VVY.AS and the average price target is 5.95 EUR. This implies a price increase of 331.78% is expected in the next year compared to the current price of 1.378.
VVY.AS Groups
Sector & Classification
VVY.AS Financial Highlights
Over the last trailing twelve months VVY.AS reported a non-GAAP Earnings per Share(EPS) of -0.48. The EPS increased by 60% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -194.47% | ||
| ROE | -392.42% | ||
| Debt/Equity | 0 |
VVY.AS Ownership
VVY.AS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 26.27 | 39.16B | ||
| ARGX | ARGENX SE | 25.57 | 39.147B | ||
| 22UA | BIONTECH SE-ADR | N/A | 18.84B | ||
| 2X1 | ABIVAX SA | N/A | 7.623B | ||
| ABVX | ABIVAX SA | N/A | 7.615B | ||
| GLPG | GALAPAGOS NV | N/A | 1.846B | ||
| GXE | GALAPAGOS NV | N/A | 1.846B | ||
| NANO | NANOBIOTIX | N/A | 1.403B | ||
| IVA | INVENTIVA SA | N/A | 1.147B | ||
| 6IV | INVENTIVA SA | N/A | 1.114B | ||
| PHIL | PHILOGEN SPA | 18.21 | 666.672M | ||
| XUP | GENFIT | N/A | 468.027M | ||
| GNFT | GENFIT | 855.39 | 448.276M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Amsterdam Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About VVY.AS
Company Profile
Vivoryon Therapeutics NV is a biopharmaceutical company, which engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. The company is headquartered in Halle, Sachsen-Anhalt and currently employs 14 full-time employees. The company went IPO on 2014-10-27. The firm has established a pipeline of orally available small molecule inhibitors for various indications, focused on oral small molecule-based therapeutics with a differentiated mode of action for treating diseases with inflammatory and/or fibrotic components, such as chronic diseases of the kidney or liver. The company focuses on chronic kidney disease (CKD), and more precisely- are initially targeting stage 3b and worse diabetic kidney disease (DKD). In addition to developing small molecule-based medicines, the Company is also pursuing antibody-based approaches for Alzheimer’s disease (AD).
Company Info
IPO: 2014-10-27
VIVORYON THERAPEUTICS NV
Weinbergweg 22
HALLE SACHSEN-ANHALT DE
Employees: 14
Phone: 493455559900
VIVORYON THERAPEUTICS NV / VVY.AS FAQ
What does VIVORYON THERAPEUTICS NV do?
Vivoryon Therapeutics NV is a biopharmaceutical company, which engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. The company is headquartered in Halle, Sachsen-Anhalt and currently employs 14 full-time employees. The company went IPO on 2014-10-27. The firm has established a pipeline of orally available small molecule inhibitors for various indications, focused on oral small molecule-based therapeutics with a differentiated mode of action for treating diseases with inflammatory and/or fibrotic components, such as chronic diseases of the kidney or liver. The company focuses on chronic kidney disease (CKD), and more precisely- are initially targeting stage 3b and worse diabetic kidney disease (DKD). In addition to developing small molecule-based medicines, the Company is also pursuing antibody-based approaches for Alzheimer’s disease (AD).
What is the stock price of VIVORYON THERAPEUTICS NV today?
The current stock price of VVY.AS is 1.378 EUR. The price decreased by -0.43% in the last trading session.
What is the dividend status of VIVORYON THERAPEUTICS NV?
VVY.AS does not pay a dividend.
What is the ChartMill technical and fundamental rating of VVY stock?
VVY.AS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the number of employees for VIVORYON THERAPEUTICS NV?
VIVORYON THERAPEUTICS NV (VVY.AS) currently has 14 employees.
What is the next earnings date for VVY stock?
VIVORYON THERAPEUTICS NV (VVY.AS) will report earnings on 2026-04-27, after the market close.